The groundbreaking rise of Sildenafil presented a significant prospect for shareholders , but its period has ended, creating a challenging landscape. Alternative versions have appeared in the market , diminishing revenues and putting a strain on profit percentages . While leading healthcare companies maintain a foothold in this field , the potentia